Bristol-Myers Squibb Stock News

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARE--Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of advanced ROS1-Positive Non-Small Cell Lung Cancer.

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs, 1-1/2 months after a federal judge abruptly dismissed an earlier version of the case.

They're down, but they aren't out, at least not in the eyes of patient investors.

Recent trial failures over at pharma giant AbbVie Inc have created a window of opportunity for competitor Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP), is analysts at UBS are to be believed. AbbVie stock took a $38 billion hit on Monday after the company revealed that Phase 2 trials of its emraclidine schizophrenia treatment have failed to meet their primary endpoint objectives.

AbbVie's “pain” is Bristol Myers Squibb's “gain,” says Truist Securities analyst Srikripa Devarakonda.

Bristol Myers Squibb stock (NYSE: BMY) was up 10% on Monday, November 11, after its peer AbbVie (NYSE; ABBV) announced that two of its mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their primary goal. [1] Emraclidine was developed by Cerevel Therapeutics, which AbbVie acquired for around $9 billion earlier this year.

Bristol-Myers Squibb Company (NYSE:BMY ) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Company Participants Samit Hirawat - EVP, Chief Medical Officer, Global Drug Development Robert Plenge - EVP, Chief Research Officer Conference Call Participants Seamus Fernandez - Guggenheim Seamus Fernandez Okay. So, in the interest of staying on time here, r...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.